Drugs & Aging

, Volume 26, Issue 1, pp 77–85

Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium

A Prospective, Open-Label, Observational Study

Authors

  • Avi Levin
    • Department of MedicineHadassah University Hospital
  • Moshe Ben-Artzi
    • Department of MedicineHadassah University Hospital
  • Pazit Beckerman
    • Department of MedicineHadassah University Hospital
  • Guy Haber
    • Department of MedicineHadassah University Hospital
  • David Varon
    • Department of HematologyHadassah University Hospital
  • Arie Ben-Yehuda
    • Department of MedicineHadassah University Hospital
    • Department of MedicineHadassah University Hospital
    • Division of Clinical PharmacologyHadassah University Hospital
Original Research Article

DOI: 10.2165/0002512-200926010-00006

Cite this article as:
Levin, A., Ben-Artzi, M., Beckerman, P. et al. Drugs Aging (2009) 26: 77. doi:10.2165/0002512-200926010-00006

Abstract

Background

Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome.

Objective

To evaluate whether weight, age and renal function are associated with anti-factor Xa activity and with bleeding in elderly patients treated with enoxaparin sodium.

Method

This was a prospective observational study of 156 elderly patients admitted consecutively to a general internal medicine ward with creatinine clearance >30 mL/min who were treated with enoxaparin sodium twice daily. Anti-factor Xa activity and bleeding events were documented in all patients. Statistical analyses were conducted to determine the effects of clinical characteristics such as renal dysfunction, age and bodyweight on these parameters.

Results

156 patients (60% males, mean age 71.0 ± 15.98 years) were studied. Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61–0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81–1.1 mg/kg/12h. Minor or major bleeding was observed in 5.8% of patients, and was associated with a lower mean bodyweight (61.89 ± 13.35 vs 74.30 ± 13.24 kg for patients with no bleeding; ? = 0.014). Bodyweight ≤55 kg was associated with bleeding with an odds ratio of 5.63 (95% CI 1.2, 25, p = 0.025).

Conclusion

Low bodyweight is associated with a greater risk of bleeding despite a reduction in enoxaparin sodium dose according to weight. This finding supports the possibility that low bodyweight is an independent risk factor for enoxaparin sodium-related bleeding.

Copyright information

© Adis Data Information BV 2009